Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma
Background - Effective treatment options are limited for patients with advanced melanoma who have progressed on immune checkpoint inhibitors (ICI) and targeted therapies (TT). Preclinical models support the combination of ICI with TT; however, clinical trials evaluating the efficacy of triplet combi...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
May 2024
|
| In: |
European journal of cancer
Year: 2024, Volume: 202, Pages: 1-9 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2024.113976 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.ejca.2024.113976 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804924001321 
|
| Author Notes: | Lea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, Jessica C. Hassel, Michael Erdmann, Andrea Forschner, Douglas B. Johnson, Renáta Váraljai, Georg Lodde, Jan Malte Placke, Frederik Krefting, Anne Zaremba, Selma Ugurel, Alexander Roesch, Carsten Schulz, Carola Berking, Christoph Pöttgen, Alexander M. Menzies, Georgina V. Long, Reinhard Dummer, Elisabeth Livingstone, Dirk Schadendorf, Lisa Zimmer |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1910015180 | ||
| 003 | DE-627 | ||
| 005 | 20251111093013.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 241202s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2024.113976 |2 doi | |
| 035 | |a (DE-627)1910015180 | ||
| 035 | |a (DE-599)KXP1910015180 | ||
| 035 | |a (OCoLC)1528014446 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Albrecht, Lea Jessica |e VerfasserIn |0 (DE-588)1267286245 |0 (DE-627)1815769122 |4 aut | |
| 245 | 1 | 0 | |a Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma |c Lea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, Jessica C. Hassel, Michael Erdmann, Andrea Forschner, Douglas B. Johnson, Renáta Váraljai, Georg Lodde, Jan Malte Placke, Frederik Krefting, Anne Zaremba, Selma Ugurel, Alexander Roesch, Carsten Schulz, Carola Berking, Christoph Pöttgen, Alexander M. Menzies, Georgina V. Long, Reinhard Dummer, Elisabeth Livingstone, Dirk Schadendorf, Lisa Zimmer |
| 264 | 1 | |c May 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 02.12.2024 | ||
| 520 | |a Background - Effective treatment options are limited for patients with advanced melanoma who have progressed on immune checkpoint inhibitors (ICI) and targeted therapies (TT). Preclinical models support the combination of ICI with TT; however, clinical trials evaluating the efficacy of triplet combinations in first-line setting showed limited advantage compared to TT only. - Methods - We conducted a retrospective, multicenter study, that included patients with advanced melanoma who were treated with BRAF/MEK inhibitors in combination with an anti-PD-(L)1 antibody (triplet therapy) after failure of at least one anti-PD-(L)1-based therapy and one TT in seven major melanoma centers between February 2016 and July 2022. - Results - A total of 48 patients were included, of which 32 patients, 66.7% had brain metastases, 37 patients (77.1%) had three or more metastatic organs and 21 patients (43.8%) had three or more treatment lines. The median follow-up time was 31.4 months (IQR, 22.27-40.45 months). The treatment with triplet therapy resulted in an ORR of 35.4% (n = 17) and a DCR of 47.9% (n = 23). The median DOR was 5.9 months (range, 3.39-14.27 months). Patients treated with BRAF/MEK inhibitors as the last treatment line showed a slightly lower ORR (29.6%) compared to patients who received ICI or chemotherapy last (ORR: 42.9%). Grade 3-4 treatment-related adverse events occurred in 25% of patients (n = 12), with seven patients (14.6%) requiring discontinuation of treatment with both or either drug. - Conclusions - Triplet therapy has shown activity in heavily pretreated patients with advanced melanoma and may represent a potential treatment regimen after failure of ICI and TT. | ||
| 650 | 4 | |a Advanced melanoma | |
| 650 | 4 | |a Anti-PD-(L)1 plus BRAF/MEK inhibitors | |
| 650 | 4 | |a Anti-PD-1 resistance | |
| 650 | 4 | |a BRAF V600 mutation | |
| 650 | 4 | |a Triplet combination | |
| 650 | 4 | |a Triplet therapy | |
| 700 | 1 | |a Dimitriou, Florentia |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grover, Piyush |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hassel, Jessica C. |d 1975- |e VerfasserIn |0 (DE-588)129790702 |0 (DE-627)480399069 |0 (DE-576)29783715X |4 aut | |
| 700 | 1 | |a Erdmann, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Forschner, Andrea |e VerfasserIn |4 aut | |
| 700 | 1 | |a Johnson, Douglas B. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Váraljai, Renáta |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lodde, Georg |e VerfasserIn |4 aut | |
| 700 | 1 | |a Placke, Jan Malte |e VerfasserIn |4 aut | |
| 700 | 1 | |a Krefting, Frederik |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zaremba, Anne |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ugurel, Selma |d 1971- |e VerfasserIn |0 (DE-588)122030923 |0 (DE-627)081693532 |0 (DE-576)293057567 |4 aut | |
| 700 | 1 | |a Roesch, Alexander |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schulz, Carsten |e VerfasserIn |0 (DE-588)1059230739 |0 (DE-627)798164573 |0 (DE-576)415234050 |4 aut | |
| 700 | 1 | |a Berking, Carola |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pöttgen, Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Menzies, Alexander M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Long, Georgina V. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dummer, Reinhard |e VerfasserIn |4 aut | |
| 700 | 1 | |a Livingstone, Elisabeth |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schadendorf, Dirk |d 1960- |e VerfasserIn |0 (DE-588)11142576X |0 (DE-627)499566076 |0 (DE-576)289702275 |4 aut | |
| 700 | 1 | |a Zimmer, Lisa |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 202(2024) vom: Mai, Artikel-ID 113976, Seite 1-9 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma |
| 773 | 1 | 8 | |g volume:202 |g year:2024 |g month:05 |g elocationid:113976 |g pages:1-9 |g extent:9 |a Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2024.113976 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0959804924001321 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20241202 | ||
| 993 | |a Article | ||
| 994 | |a 2024 | ||
| 998 | |g 11142576X |a Schadendorf, Dirk |m 11142576X:Schadendorf, Dirk |d 50000 |e 50000PS11142576X |k 0/50000/ |p 22 | ||
| 998 | |g 1059230739 |a Schulz, Carsten |m 1059230739:Schulz, Carsten |d 910000 |d 911300 |e 910000PS1059230739 |e 911300PS1059230739 |k 0/910000/ |k 1/910000/911300/ |p 15 | ||
| 998 | |g 122030923 |a Ugurel, Selma |m 122030923:Ugurel, Selma |d 60000 |e 60000PU122030923 |k 0/60000/ |p 13 | ||
| 998 | |g 129790702 |a Hassel, Jessica C. |m 129790702:Hassel, Jessica C. |d 910000 |d 911300 |d 50000 |e 910000PH129790702 |e 911300PH129790702 |e 50000PH129790702 |k 0/910000/ |k 1/910000/911300/ |k 0/50000/ |p 4 | ||
| 999 | |a KXP-PPN1910015180 |e 4629485694 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"May 2024","dateIssuedKey":"2024"}],"relHost":[{"part":{"text":"202(2024) vom: Mai, Artikel-ID 113976, Seite 1-9","volume":"202","extent":"9","pages":"1-9","year":"2024"},"id":{"eki":["266883400"],"issn":["1879-0852"],"zdb":["1468190-0"]},"titleAlt":[{"title":"EJC online"}],"pubHistory":["28.1992 -"],"corporate":[{"role":"isb","display":"European Organization for Research on Treatment of Cancer"},{"role":"isb","display":"European Association for Cancer Research"},{"role":"isb","display":"European School of Oncology"}],"disp":"Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanomaEuropean journal of cancer","recId":"266883400","title":[{"title_sort":"European journal of cancer","title":"European journal of cancer"}],"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"origin":[{"publisher":"Elsevier ; Pergamon Press","dateIssuedDisp":"1992-","dateIssuedKey":"1992","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]"}]}],"person":[{"display":"Albrecht, Lea Jessica","role":"aut","given":"Lea Jessica","family":"Albrecht"},{"display":"Dimitriou, Florentia","family":"Dimitriou","role":"aut","given":"Florentia"},{"family":"Grover","role":"aut","given":"Piyush","display":"Grover, Piyush"},{"role":"aut","given":"Jessica C.","family":"Hassel","display":"Hassel, Jessica C."},{"family":"Erdmann","role":"aut","given":"Michael","display":"Erdmann, Michael"},{"family":"Forschner","role":"aut","given":"Andrea","display":"Forschner, Andrea"},{"family":"Johnson","role":"aut","given":"Douglas B.","display":"Johnson, Douglas B."},{"display":"Váraljai, Renáta","family":"Váraljai","given":"Renáta","role":"aut"},{"display":"Lodde, Georg","role":"aut","given":"Georg","family":"Lodde"},{"display":"Placke, Jan Malte","family":"Placke","role":"aut","given":"Jan Malte"},{"display":"Krefting, Frederik","role":"aut","given":"Frederik","family":"Krefting"},{"display":"Zaremba, Anne","role":"aut","given":"Anne","family":"Zaremba"},{"given":"Selma","role":"aut","family":"Ugurel","display":"Ugurel, Selma"},{"display":"Roesch, Alexander","family":"Roesch","role":"aut","given":"Alexander"},{"given":"Carsten","role":"aut","family":"Schulz","display":"Schulz, Carsten"},{"family":"Berking","given":"Carola","role":"aut","display":"Berking, Carola"},{"family":"Pöttgen","role":"aut","given":"Christoph","display":"Pöttgen, Christoph"},{"given":"Alexander M.","role":"aut","family":"Menzies","display":"Menzies, Alexander M."},{"display":"Long, Georgina V.","role":"aut","given":"Georgina V.","family":"Long"},{"display":"Dummer, Reinhard","role":"aut","given":"Reinhard","family":"Dummer"},{"family":"Livingstone","role":"aut","given":"Elisabeth","display":"Livingstone, Elisabeth"},{"family":"Schadendorf","given":"Dirk","role":"aut","display":"Schadendorf, Dirk"},{"family":"Zimmer","given":"Lisa","role":"aut","display":"Zimmer, Lisa"}],"title":[{"title_sort":"Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma","title":"Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma"}],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 02.12.2024"],"recId":"1910015180","physDesc":[{"extent":"9 S.","noteIll":"Illustrationen"}],"name":{"displayForm":["Lea Jessica Albrecht, Florentia Dimitriou, Piyush Grover, Jessica C. Hassel, Michael Erdmann, Andrea Forschner, Douglas B. Johnson, Renáta Váraljai, Georg Lodde, Jan Malte Placke, Frederik Krefting, Anne Zaremba, Selma Ugurel, Alexander Roesch, Carsten Schulz, Carola Berking, Christoph Pöttgen, Alexander M. Menzies, Georgina V. Long, Reinhard Dummer, Elisabeth Livingstone, Dirk Schadendorf, Lisa Zimmer"]},"id":{"eki":["1910015180"],"doi":["10.1016/j.ejca.2024.113976"]}} | ||
| SRT | |a ALBRECHTLEANTIPDL1PL2024 | ||